ID: ALA191228

Max Phase: Preclinical

Molecular Formula: C17H13ClN2O4

Molecular Weight: 344.75

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1cc(O)c(-c2[nH]ncc2-c2ccc3c(c2)OCCO3)cc1Cl

Standard InChI:  InChI=1S/C17H13ClN2O4/c18-12-6-10(13(21)7-14(12)22)17-11(8-19-20-17)9-1-2-15-16(5-9)24-4-3-23-15/h1-2,5-8,21-22H,3-4H2,(H,19,20)

Standard InChI Key:  VCOQUJZTHUQIBZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 344.75

Molecular Weight (Monoisotopic): 344.0564

AlogP: 3.58

#Rotatable Bonds: 2

Polar Surface Area: 87.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.86

CX Basic pKa: 2.07

CX LogP: 3.00

CX LogD: 2.87

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.66

Np Likeness Score: -0.49

References

1. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E, Workman P..  (2005)  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.,  15  (14): [PMID:15955698] [10.1016/j.bmcl.2005.05.046]

2. Vo CD, Shebert HL, Zikovich S, Dryer RA, Huang TP, Moran LJ, Cho J, Wassarman DR, Falahee BE, Young PD, Gu GH, Heinl JF, Hammond JW, Jackvony TN, Frederick TE, Blair JA..  (2017)  Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases.,  27  (23): [PMID:29110989] [10.1016/j.bmcl.2017.10.036]

Source

Source(1):

• Scientific Literature